CV & Diabetes Market Forecast

Publication Date	January 2009
Publisher	Datamonitor
Product Type	Interactive Model
Pages
ISBN Number	not applicable
Product Code	DAT14423

Buy this product or for assistance call +44 20 7060 7474

PDF £7,955.00$13232 | €8904

FAX Order above formats by FAX

Summary

Introduction
Datamonitor expects antidiabetic therapies to emerge as the biggest revenue earner in the cardiovascular and metabolic markets by 2017. A large and diverse development pipeline will provide a number of new blockbuster drugs but the heavy genericization of the hypertension and dyslipidemia primary care markets will lead to the overall market only growing by 0.9% in the seven major markets.

Scope

Highlights

Reasons to Purchase

A detailed clinical and commercial assessment of all key cardiovascular and metabolic therapy areas.

An analysis of the portfolios of top 10 leading cardiovascular and metabolic companies.

Sales based sales forecasts for all key cardiovascular and metabolic active agents in the seven major markets to 2017.

Content

Please note that this product is delivered as an interactive model. The model is an Excel document and its data can be manipulated and used as per your needs. The data when extracted and used must be correctly cited to the publisher. This product does not include numbers of pages due to the format that it is supplied in. Should you have any queries regarding the model or would like a demo please do not hesitate to call us on Tel: +44 (0) 20 7060 7474 or email our customer service on service@reportbuyer.com